AMRX Stock Recent News
AMRX LATEST HEADLINES
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, today announced a strategic collaboration to expand domestic production of Apiject's BFS-based injectable platform at Amneal's Brookhaven, NY facility.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.